• Tuesday, October 18, 2022 @ 12:00 am

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-04 study design of the IL-15 superagonist, SOT101 as a Trial in Progress and nonclinical data on mechanism of action of its BOXR T cell platform, at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.

The study design of AURELIO-04 will be presented by Aurélien Marabelle, M.D., Ph.D., immuno-oncologist from the Drug Development Department at Gustave Roussy Cancer Center under the title "A phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors", Abstract Number: 716.

Findings from the study of BOXR1030 will be delivered by Pratirodh Koirala, Ph.D. and John Hinds, Ph.D., translational scientists at SOTIO Biotech Inc. (U.S.) under the title "Exogenous GOT2 in CAR-T cells improves metabolic function and preserves early memory T cell subsets", Abstract Number: 238.

You may also be interested in